Evidence map›Paper›PMID 34632114›Full record

ArticleOsteoporosis and sarcopenia2021

Effects of romosozumab or denosumab treatment on the bone mineral density and disease activity for 6 months in patients with rheumatoid arthritis with severe osteoporosis: An open-label, randomized, pilot study.

Takeshi Mochizuki, Koichiro Yano, Katsunori Ikari, Ken Okazaki

Registry-linked trialOpen access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Osteoporosis and sarcopenia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05103592 (Assessment of Tartrate- Resistant Acid Posphatase 5b), which is not on this map. Cited by 15 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 5 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05103592 unknown statusnot on this map

Assessment of Tartrate- Resistant Acid Posphatase 5b (TRACP-5b) in Primary and Secondary Osteoprosis

TypeobservationalSponsorAssiut UniversityRan2021 to 2023Enrolled84ConditionsOsteoporosisArmsTartrate- resistant Acid Phosphatase marker
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 5 syntheses or guidelines pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Romosozumab for the treatment of osteoporosis - a systematic review.Journal of endocrinological investigation · 2025
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Bone Health in Rheumatoid Arthritis: An Update.Current rheumatology reports · 2026
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Romosozumab in osteoporosis: yesterday, today and tomorrow.Journal of translational medicine · 2023
    Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Takeshi MochizukiDepartment of Orthopedic Surgery, Kamagaya General Hospital, Chiba, Japan.
Koichiro YanoDepartment of Orthopedic Surgery, Tokyo Women's Medical University, Tokyo, Japan.
Katsunori IkariDepartment of Orthopedic Surgery, Tokyo Women's Medical University, Tokyo, Japan.
Ken OkazakiDepartment of Orthopedic Surgery, Tokyo Women's Medical University, Tokyo, Japan.
Tokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate effects of romosozumab treatment on disease activity and bone mineral density (BMD) in patients with rheumatoid arthritis (RA) and severe osteoporosis in comparison with effects of denosumab treatment.

methodsA total of 50 women were enrolled in this study. The subjects were randomized equally into 2 groups: the romosozumab group or the denosumab group. Disease activity score in 28 joints (DAS28)-erythrocyte sedimentation rate (ESR) and BMD at lumbar spine were evaluated.

resultsThe percent changes (Δ) in the BMD values at 3 and 6 months for the lumbar spine were as follows: romosozumab; 4.9% and 5.2%, denosumab: 2.3% and 3.2%. The ΔBMD for the lumbar spine at 3 months was significantly higher in the romosozumab group than in the denosumab group (P = 0.044). The DAS28-ESR at baseline, 3 and 6 months in the romosozumab group were 2.88, 2.60 (P = 0.427) and 2.58 (P = 0.588), respectively. The change from baseline in DAS28-ESR did not differ significantly between these 2 groups at any time point.

conclusionsThe present study revealed that romosozumab treatment is more effective than denosumab treatment in increasing BMD of the lumbar spine at 3 months. Furthermore, the present study suggested that romosozumab treatment has no effects on the disease activity of RA in patients with RA and severe osteoporosis for 6 months.

Indexed as

Bone mineral densityDisease activityOsteoporosisRheumatoid arthritisRomosozumab

Identifiers

PMID34632114
PMCPMC8486617
OpenAlexW3197027587

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.